Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-period randomized withdrawal study of MAS825 in NLRC4-GOF
2020-003596-17Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in NLRC4-associated autoinflammatory disease (NLRC4-AID) and necrotizing enterocolitis (NEC) comparing MAS825 with Placebo (2 arms). Primary endpoint: Occurrence of disease flare during randomized withdrawal period. Started Jan 2021; status: active.
02
Drugs
MAS825
03
Conditions
NLRC4-associated autoinflammatory disease (NLRC4-AID)necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on 2020-003596-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003596-17.